Literature DB >> 29222262

Pediatric leukemia susceptibility disorders: manifestations and management.

Lisa J McReynolds1, Sharon A Savage1.   

Abstract

The clinical manifestations of inherited susceptibility to leukemia encompass a wide phenotypic range, including patients with certain congenital anomalies or early-onset myelodysplastic syndrome (MDS) and some with no obvious medical problems until they develop leukemia. Leukemia susceptibility syndromes occur as a result of autosomal dominant, autosomal recessive, or X-linked recessive inheritance, or de novo occurrence, of germline pathogenic variants in DNA repair, ribosome biogenesis, telomere biology, hematopoietic transcription factors, tumor suppressors, and other critical cellular processes. Children and adults with cytopenias, MDS, dysmorphic features, notable infectious histories, immunodeficiency, certain dermatologic findings, lymphedema, unusual sensitivity to radiation or chemotherapy, or acute leukemia with a family history of early-onset cancer, pulmonary fibrosis, or alveolar proteinosis should be thoroughly evaluated for a leukemia susceptibility syndrome. Genetic testing and other diagnostic modalities have improved our ability to identify these patients and to counsel them and their family members for subsequent disease risk, cancer surveillance, and therapeutic interventions. Herein, the leukemia susceptibility syndromes are divided into 3 groups: (1) those associated with an underlying inherited bone marrow failure syndrome, (2) disorders in which MDS precedes leukemia development, and (3) those with a risk primarily of leukemia. Although children are the focus of this review, it is important for clinicians to recognize that inherited susceptibility to cancer can present at any age, even in older adults; genetic counseling is essential and prompt referral to experts in each syndrome is strongly recommended.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29222262      PMCID: PMC6142612          DOI: 10.1182/asheducation-2017.1.242

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  40 in total

1.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

Review 2.  The molecular genetics of the telomere biology disorders.

Authors:  Alison A Bertuch
Journal:  RNA Biol       Date:  2015-09-23       Impact factor: 4.652

Review 3.  Predisposition to pediatric and hematologic cancers: a moving target.

Authors:  David Malkin; Kim E Nichols; Kristin Zelley; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

4.  Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome.

Authors:  Santhosh Dhanraj; Anna Matveev; Hongbing Li; Supanun Lauhasurayotin; Lawrence Jardine; Michaela Cada; Bozana Zlateska; Chetankumar S Tailor; Joseph Zhou; Roberto Mendoza-Londono; Ajoy Vincent; Peter R Durie; Stephen W Scherer; Johanna M Rommens; Elise Heon; Yigal Dror
Journal:  Blood       Date:  2017-01-06       Impact factor: 22.113

5.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

Review 6.  TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Authors:  Evan Q Comeaux; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

Review 7.  Fanconi anemia and the development of leukemia.

Authors:  Blanche P Alter
Journal:  Best Pract Res Clin Haematol       Date:  2014-10-15       Impact factor: 3.020

8.  Germline PAX5 mutations and B cell leukemia.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

9.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

Review 10.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

View more
  6 in total

Review 1.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 2.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

3.  Genetic predisposition to MDS: diagnosis and management.

Authors:  Elissa Furutani; Akiko Shimamura
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 4.  Zebrafish Cancer Predisposition Models.

Authors:  Kim Kobar; Keon Collett; Sergey V Prykhozhij; Jason N Berman
Journal:  Front Cell Dev Biol       Date:  2021-04-27

5.  Increased Cancer Prevalence in Peripartum Cardiomyopathy.

Authors:  Tobias J Pfeffer; Stella Schlothauer; Stefan Pietzsch; Maria Schaufelberger; Bernd Auber; Melanie Ricke-Hoch; Manuel List; Dominik Berliner; Valeska Abou Moulig; Tobias König; Zolt Arany; Karen Sliwa; Johann Bauersachs; Denise Hilfiker-Kleiner
Journal:  JACC CardioOncol       Date:  2019-12-17

6.  [Diagnosis and treatment of acute leukemia during pregnancy].

Authors:  N Peng; M Y Liang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.